Results 131 to 140 of about 377 (154)
Some of the next articles are maybe not open access.
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
LONG-TERM SAFETY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM ANALYSIS OF DATA FROM RESTORE
Chest, 2022THOMAS P STERN +7 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +1 more source
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Analysis of Data From RESTORE (P5-13.005)
Neurology, 2023Thomas Stern +8 more
openaire +1 more source
SLEEP
Abstract Introduction In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
Bruce Corser +8 more
openaire +1 more source
Abstract Introduction In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
Bruce Corser +8 more
openaire +1 more source
Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults
Clinical Therapeutics, 2021David Seiden
exaly
SLEEP
Abstract Introduction Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those with an apnea hypopnea index (AHI)
Richard Bogan +5 more
openaire +1 more source
Abstract Introduction Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those with an apnea hypopnea index (AHI)
Richard Bogan +5 more
openaire +1 more source
Dose titration of once-nightly sodium oxybate: analysis of interim data from RESTORE
Sleep MedicineA. Roy +5 more
openaire +1 more source